Results 161 to 170 of about 169,795 (221)

Long‐term safety and efficacy of subcutaneous implantable cardioverter‐defibrillator compared with transvenous implantable cardioverter‐defibrillator in propensity score‐matched patients from Japan

Journal of Arrhythmia, Volume 41, Issue 2, April 2025.
In propensity score‐matched Japanese patients with S‐ICD, the cumulative incidence of ICD shock therapies and mortality was comparable to those with TV‐ICD. Notably, patients with S‐ICD had fewer lead‐related complications than those with TV‐ICD. Abstract Background Subcutaneous implantable cardioverter‐defibrillator (S‐ICD) has been reported to be non‐
Yuki Konno, Shingo Sasaki, Yuji Ishida, Yuichi Toyama, Kimitaka Nishizaki, Takahiko Kinjo, Taihei Itoh, Masaomi Kimura, Kazufumi Kato, Toshihiro Iwasaki, Hitoshi Umezaki, Shun Hirosawa, Hirofumi Tomita   +12 more
wiley   +1 more source

NovelKCNQ1 mutations associated with recessive and dominant congenital long QT Syndromes: Evidence for variable hearing phenotype associated with R518X [PDF]

, 2000
Jian Wei, Frank A. Fish, Robert J. Myerburg, Dan M. Roden, Alfred L. George   +4 more
openalex   +1 more source

Novel Co‐Occurrence of Trisomy 21 and Heterozygous CFTR Mutation

Respirology Case Reports, Volume 13, Issue 4, April 2025.
This article reports a novel co‐occurrence of trisomy 21 and a heterozygous CFTR mutation in an infant. ABSTRACT The coexistence of trisomy 21 and cystic fibrosis (CF) is extremely rare, with fewer than 10 reported cases, all involving homozygous CFTR mutations.
Majd Oweidat, Tamer Qutaina, Alzahra Akram Hamdan, Fatima Zain Hanini   +3 more
wiley   +1 more source

Response of the QT interval to mental and physical stress in types LQT1 and LQT2 of the long QT syndrome [PDF]

, 2001
Kristian Paavonen, Heikki Swan, Kirsi Piippo, Laura Hokkanen, Päivi Laitinen, Matti Viitasalo, L. Toivonen, Kimmo Kontula   +7 more
openalex   +3 more sources

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

British Journal of Haematology, Volume 206, Issue 4, Page 1121-1128, April 2025.
Outcomes with olutasidenib appear appreciably better than previous reports of other therapies for blast‐phase myeloproliferative neoplasm (MPN), supporting the role for olutasidenib‐based therapy in mIDH1 AML secondary to MPN. Summary Acute myeloid leukaemia (AML) arising from a myeloproliferative neoplasm (MPN) is more aggressive and less responsive ...
Stéphane De Botton, Christian Récher, Jorge Cortes, Antonio Curti, Pierre Fenaux, Pierre Peterlin, Arnaud Pigneux, Karen Yee, Andrew Wei, Alice Mims, Gary Schiller, Mwe Mwe Chao, Hua Tian, Justin M. Watts   +13 more
wiley   +1 more source

A de novo missense mutation (R1623Q) of the SCN5A gene in a Japanese girl with sporadic long QT syndrome

, 1998
Hiroyuki Yamagishi, Michiko Furutani, Mitsuhiro Kamisago, Yoshiyuki Morikawa, Yoshifumi Kojima, Yoshiaki Hino, Yoshiyuki Furutani, Misa Kimura, Shin‐ichiro Imamura, Atsuyoshi Takao, Kazuo Momma, Rumiko Matsuoka   +11 more
openalex   +1 more source

Analysis of the human KCNH2(HERG) gene: Identification and characterization of a novel mutation Y667X associated with long QT syndrome and a non-pathological 9 bp insertion Communicated by: Mark H. Paalman Online Citation: Human Mutation, Mutation in Brief #325 (2000) Online http://journals.wiley.com/1059-7794/pdf/mutation/325.pdf [PDF]

, 2000
Aimée Paulussen, Ping Yang, Menelas N. Pangalos, Peter Verhasselt, Roger Marrannes, Christel Verfaille, Ine Vandenberk, Raf Crabbe, Frank Konings, Walter Luyten, Martin Armstrong   +10 more
openalex   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Arrhythomogenic substrate for cardiomyopathies: Arrhythmogenic right ventricular cardiomyopathy/dysplasia and idiopathic long QT syndrome.

, 1999
Sachio Kawai
openalex   +2 more sources

Applications, challenges and future directions of artificial intelligence in cardio‐oncology

European Journal of Clinical Investigation, Volume 55, Issue S1, April 2025.
Abstract Background The management of cardiotoxicity related to cancer therapies has emerged as a significant clinical challenge, prompting the rapid growth of cardio‐oncology. As cancer treatments become more complex, there is an increasing need to enhance diagnostic and therapeutic strategies for managing their cardiovascular side effects.
Francesco Ravera, Nicolò Gilardi, Alberto Ballestrero, Gabriele Zoppoli   +3 more
wiley   +1 more source